ImmunoGen (IMGN) Gets a Hold Rating from Cowen & Co.


In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on ImmunoGen (IMGN). The company’s shares opened today at $5.46.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.2% and a 42.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ImmunoGen with a $16 average price target.

See today’s analyst top recommended stocks >>

Based on ImmunoGen’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $46.81 million. In comparison, last year the company had a GAAP net loss of $13.12 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779, and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts